Matches in Wikidata for { <http://www.wikidata.org/entity/Q92906850> ?p ?o ?g. }
Showing items 1 to 43 of
43
with 100 items per page.
- Q92906850 description "artículu científicu espublizáu en xunu de 2019" @default.
- Q92906850 description "scientific article published on 17 June 2019" @default.
- Q92906850 description "wetenschappelijk artikel" @default.
- Q92906850 description "наукова стаття, опублікована 17 червня 2019" @default.
- Q92906850 name "Crystalline adduct of moxifloxacin with trans-cinnamic acid to reduce the aqueous solubility and dissolution rate for improved residence time in the lungs" @default.
- Q92906850 name "Crystalline adduct of moxifloxacin with trans-cinnamic acid to reduce the aqueous solubility and dissolution rate for improved residence time in the lungs" @default.
- Q92906850 type Item @default.
- Q92906850 label "Crystalline adduct of moxifloxacin with trans-cinnamic acid to reduce the aqueous solubility and dissolution rate for improved residence time in the lungs" @default.
- Q92906850 label "Crystalline adduct of moxifloxacin with trans-cinnamic acid to reduce the aqueous solubility and dissolution rate for improved residence time in the lungs" @default.
- Q92906850 prefLabel "Crystalline adduct of moxifloxacin with trans-cinnamic acid to reduce the aqueous solubility and dissolution rate for improved residence time in the lungs" @default.
- Q92906850 prefLabel "Crystalline adduct of moxifloxacin with trans-cinnamic acid to reduce the aqueous solubility and dissolution rate for improved residence time in the lungs" @default.
- Q92906850 P1433 Q92906850-67794FCA-C580-408A-A200-180D2C7C7735 @default.
- Q92906850 P1476 Q92906850-9E2D6AA1-BBA6-45A4-9D48-893D6CC52513 @default.
- Q92906850 P2093 Q92906850-301BF2C8-F0FE-4BB3-8038-E7B0375FFDF4 @default.
- Q92906850 P2093 Q92906850-356231E7-659F-4FC0-B6DE-0258E7B239BA @default.
- Q92906850 P2093 Q92906850-A5885C5E-6A0C-4279-BAFC-554D6BAC5A23 @default.
- Q92906850 P2093 Q92906850-A995F51C-697C-4115-A83D-CAD0E9B99972 @default.
- Q92906850 P2093 Q92906850-D5A9553D-6C8C-4F29-847E-291B255EA56A @default.
- Q92906850 P304 Q92906850-4ED826DA-AFD0-4F1F-BDF3-0FEEBEC896D2 @default.
- Q92906850 P31 Q92906850-080954F4-5EFF-49D7-BE5C-75A1E771B7B1 @default.
- Q92906850 P356 Q92906850-31251C8A-07DE-4FFD-B4BB-838030AFA300 @default.
- Q92906850 P478 Q92906850-CF951556-4CED-4A40-BDBD-9CFC6AA30C21 @default.
- Q92906850 P50 Q92906850-F429D90C-B16E-4D9D-B280-CD162DEB614E @default.
- Q92906850 P577 Q92906850-1BB344FE-D7E5-488A-BDBA-3BF11D7890F5 @default.
- Q92906850 P698 Q92906850-788E4741-9040-4B55-9A30-620D723A5069 @default.
- Q92906850 P921 Q92906850-45DA9E12-10B3-4F48-B03D-0DA25C6506AA @default.
- Q92906850 P356 J.EJPS.2019.104961 @default.
- Q92906850 P698 31220546 @default.
- Q92906850 P1433 Q5412738 @default.
- Q92906850 P1476 "Crystalline adduct of moxifloxacin with trans-cinnamic acid to reduce the aqueous solubility and dissolution rate for improved residence time in the lungs" @default.
- Q92906850 P2093 "Basanth Babu Eedara" @default.
- Q92906850 P2093 "Ian G Tucker" @default.
- Q92906850 P2093 "Jason R Price" @default.
- Q92906850 P2093 "Shyamal C Das" @default.
- Q92906850 P2093 "Zoran D Zujovic" @default.
- Q92906850 P304 "104961" @default.
- Q92906850 P31 Q13442814 @default.
- Q92906850 P356 "10.1016/J.EJPS.2019.104961" @default.
- Q92906850 P478 "136" @default.
- Q92906850 P50 Q37828574 @default.
- Q92906850 P577 "2019-06-17T00:00:00Z" @default.
- Q92906850 P698 "31220546" @default.
- Q92906850 P921 Q424940 @default.